Informação sobre produto
- 2-Methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E,42E,46E)-3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl-2,6,10,14,18,22,26,30 ,34,38,42,46,50-dopentacontatridecaenyl]-1,4-naphthalenedioneMK 13
- 1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl-2,6,10,14,18,22,26,30,34,38,42,46,50-dopentacontatridecaenyl)-,(all-E)-
- 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl-2,6,10,14,18,22,26,30,34,38,42,46,50-dopentacontatridecaenyl)-(8CI)
- Mk 13
Menaquinone 13 is a vitamin K2 that is involved in the post-translational carboxylation of the glutamic acid residues on specific proteins. It has been shown to be a potent inhibitor of epidermal growth factor (EGF) and can be used for the treatment of cancer. Menaquinone 13 inhibits bacterial growth by binding to DNA-dependent RNA polymerase, thereby preventing transcription and replication. The high frequency of human activity has been shown using a patch-clamp technique on human erythrocytes. This active form is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. Menaquinone 13 also specifically binds to markers expressed at high levels in Mycobacterium tuberculosis strains (e.g., ESX-1 secretion system protein) and inhibits
Propriedades químicas
Consulta técnica sobre: 3D-FM25051 Menaquinone 13
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.